[Comparison of the efficacy and safety of Bortezomib between the twice-weekly and once-weekly regimens for newly diagnosed multiple myeloma].
Z. G. Liu
Zhonghua xue ye xue za zhi = Zhonghua xueyexue…
View on PubMed
Abstract & Figures
Sorry, we couldn't extract an abstract for this paper.
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.
Sorry, we couldn't extract any citations for this paper.
Sorry, we couldn't extract any references for this paper.
Loading similar papers…
Slides referencing similar topics
Upfront Management of Newly Diagnosed Multiple Myeloma (Module 1)
Nov 07, 2017
Management of Multiple Myeloma : The Changing Paradigm Frontline Therapy for Newly Diagnosed Patients
Oct 17, 2017
Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: Results of an interim analysis of the German DSMM Xia trial
Rafael Fonseca + 10 • Nov 03, 2017